Thr555
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr555  -  HIF1A (human)

Site Information
NPFsTQDtDLDLEML   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 34362821

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
brain cancer ( 2 ) , glioblastoma ( 2 ) , glioma ( 2 ) , breast cancer ( 1 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on HIF1A:
protein degradation ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , signaling pathway regulation ( 1 )

References 

1

Li AG, et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation. Proc Natl Acad Sci U S A 115, E9600-E9609
30254159   Curated Info

2

Stokes M (2007) CST Curation Set: 2262; Year: 2007; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info